Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
Plasma p-tau217-based biomarkers accurately reflect PET-based staging across frameworks. The convergent therapeutic window thresholds demonstrate robust biological transitions, enabling accessible identification of optimal candidates for disease-modifying therapies.
Authors
- Philip B. Verghese (ORCID: https://orcid.org/0000-0003-4793-564X)
- You Jin Kim (ORCID: https://orcid.org/0000-0002-4952-5532)
- Kristopher M. Kirmess (ORCID: https://orcid.org/0000-0002-0306-323X)
- Joel B. Braunstein (ORCID: https://orcid.org/0000-0002-1155-0206)
- Han‐Kyeol Kim (ORCID: https://orcid.org/0000-0002-7650-6708)
- Mina Park (ORCID: https://orcid.org/0000-0003-1217-5644)
- Hanna Cho (ORCID: https://orcid.org/0000-0002-5339-2541)
- Tim West
- Daniel Connell
- Joong‐Hyun Chun
- Chul Hyoung Lyoo
- Jae Hoon Lee
- Young Hoon Ryu
Institutions
- Severance Hospital (KR)
- C2N Diagnostics (United States) (US)
- Wonju Severance Christian Hospital (KR)
- Gangnam Severance Hospital (KR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/alz.71199
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00